Recombinant Human Protein NOV homolog protein (NOV) (Active)

In Stock
Code CSB-AP002511HU
Size $142
Order now
Have Questions? Leave a Message or Start an on-line Chat

Product Details

>95% as determined by SDS-PAGE.
Less than 1.0 EU/μg as determined by LAL method.
Fully biologically active when compared to standard. The ED50 as determined by a cell proliferation assay using murine Balb/c 3T3 cells is less than 1.0 μg/ml, corresponding to a specific activity of >1000 IU/mg.
Target Names
Uniprot No.
Research Area
Alternative Names
CCN family member 3; CCN3; IBP-9; IGF-binding protein 9; IGFBP-9; IGFBP9; Insulin-like growth factor-binding protein 9; Nephroblastoma overexpressed; Nephroblastoma overexpressed gene protein homolog; Nephroblastoma-overexpressed gene protein homolog; NOV; NOV_HUMAN; NovH; Protein NOV homolog
Homo sapiens (Human)
Expression Region
Complete Sequence
Mol. Weight
36.2 kDa
Protein Length
Full Length of Mature Protein
Tag Info
Lyophilized powder
Lyophilized from a 0.2 µm filtered PBS, pH 7.0
We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Please reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL.We recommend to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C/-80°C. Our default final concentration of glycerol is 50%. Customers could use it as reference.
Troubleshooting and FAQs
Storage Condition
Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. Avoid repeated freeze-thaw cycles.
Shelf Life
The shelf life is related to many factors, storage state, buffer ingredients, storage temperature and the stability of the protein itself.
Generally, the shelf life of liquid form is 6 months at -20°C/-80°C. The shelf life of lyophilized form is 12 months at -20°C/-80°C.
Lead Time
5-10 business days
Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.
Datasheet & COA
Please contact us to get it.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Immediate-early protein playing a role in various cellular processes including proliferation, adhesion, migration, differentiation and survival. Acts by binding to integrins or membrane receptors such as NOTCH1. Essential regulator of hematopoietic stem and progenitor cell function. Inhibits myogenic differentiation through the activation of Notch-signaling pathway. Inhibits vascular smooth muscle cells proliferation by increasing expression of cell-cycle regulators such as CDKN2B or CDKN1A independently of TGFB1 signaling. Ligand of integrins ITGAV:ITGB3 and ITGA5:ITGB1, acts directly upon endothelial cells to stimulate pro-angiogenic activities and induces angiogenesis. In endothelial cells, supports cell adhesion, induces directed cell migration (chemotaxis) and promotes cell survival. Plays also a role in cutaneous wound healing acting as integrin receptor ligand. Supports skin fibroblast adhesion through ITGA5:ITGB1 and ITGA6:ITGB1 and induces fibroblast chemotaxis through ITGAV:ITGB5. Seems to enhance bFGF-induced DNA synthesis in fibroblasts. Involved in bone regeneration as a negative regulator. Enhances the articular chondrocytic phenotype, whereas it repressed the one representing endochondral ossification. Impairs pancreatic beta-cell function, inhibits beta-cell proliferation and insulin secretion. Plays a role as negative regulator of endothelial pro-inflammatory activation reducing monocyte adhesion, its anti-inflammatory effects occur secondary to the inhibition of NF-kappaB signaling pathway. Contributes to the control and coordination of inflammatory processes in atherosclerosis. Attenuates inflammatory pain through regulation of IL1B- and TNF-induced MMP9, MMP2 and CCL2 expression. Inhibits MMP9 expression through ITGB1 engagement.
Gene References into Functions
  1. A significant reduction of CCN3 expression was observed in lesioned skin compared to non-lesioned skin in vitiligo patients. PMID: 29998862
  2. This is the first evidence of downregulation of TGFbeta1-mediated activation of a Smad1/5/8 signalling pathway by CCN3 in human podocytes and in any cell type. PMID: 29506624
  3. NOV is a novel biomarker of the presence and severity of OSA and a potential marker of future cardiovascular and metabolic disease in OSA patients. PMID: 28862983
  4. down-regulation of Lamin B1 and up-regulation of Nephroblastoma overexpressed (NOV) are at least partially responsible for the inhibitory effect of Huaier on the proliferative and invasive capacity of SKHEP-1 cells PMID: 27503760
  5. NOV is down-regulated in CRC tumours which is associated with disease progression. PMID: 28412738
  6. Taken together, our results suggest that palmitoylation by ZDHHC22 at C241 in the CCN3 TSP1 domain may be required for the secretion of CCN3. Aberrant palmitoylation induces intracellular accumulation of CCN3, inhibiting neuronal axon growth. PMID: 29287726
  7. CCN3 (Nov) and CCN5 (WISP2) are novel substrates of MMP14. PMID: 27471094
  8. Reduced levels of CCN1 and CCN3, as found in early-onset preeclampsia, could contribute to a shift from invasive to proliferative extravillous trophoblasts and may explain their shallow invasion properties in this disease. PMID: 26744771
  9. our findings establish CCN3 as a pivotal regulator of androgen receptor (AR) signaling and prostate cancer progression and suggest a functional intersection between EZH2 and AR signaling in castration-resistant prostate cancer PMID: 27815387
  10. The present study aimed to examine the clinical relevance of NOV along with CYR61 and CTGF in gastric cancer by analysing their transcript levels...the expression of NOV and CYR61 was increased in gastric cancer. The elevated expression of CYR61 was associated with poorer survival. NOV promoted proliferation and invasion of gastric cancer cells PMID: 27633176
  11. Studies indicate that the CYR61 CTGF NOV matricellular proteins (CCN family of proteins) comprises the members CCN1, CCN2, CCN3, CCN4, CCN5 and CCN6 and have been identified in various types of cancer. PMID: 26498181
  12. NOV expression was highly increased in biopsies of patients with tubulointerstitial nephritis. PMID: 26367310
  13. Results revealed that NOV regulates the tumor growth of osteosarcoma cells through activation of the MAPK signaling pathway and promotes osteosarcoma cell migration in vitro. PMID: 26238193
  14. our results argue that MZF-1 regulates the CTGF and NOV genes in the hematopoietic compartment, and may be involved in their respective functions in the stroma. PMID: 25899830
  15. Overexpression of CCN3 induces M2 macrophage infiltration and contributes to angiogenesis in prostate cancer microenvironment. PMID: 24721786
  16. NOV may promote carcinogenesis via promotion of EMT and association with increased mTOR activity PMID: 24719190
  17. over-expression of NOV in pancreatic cancer cells promoted cell proliferation and migration, while knock down the expression of NOV impaired the tumorigenecity of pancreatic cancer cells in vitro and in vivo PMID: 24258112
  18. CCN3 may play an important role in cervical carcinogenesis and therefore may have potential as a biomarker for prognosis and as a therapeutic target in cervical cancer. PMID: 24431313
  19. Our findings establish a tumor-suppressive role of NOV in prostate cancer PMID: 23318417
  20. in obese humans and mice plasma NOV levels positively correlated with NOV expression in adipose tissue, and support a possible contribution of NOV to obesity-related inflammation. PMID: 23785511
  21. These results identify CCN3, a novel transcriptional target of FoxO1 in pancreatic beta-cells. PMID: 23705021
  22. Presence of both forms of CCN3 is accompanied by a balance of trophoblast proliferation and migration/invasion properties, which are triggered by different signalling pathways. PMID: 23220688
  23. CCN3 expression is higher in highly invasive PC3 cells. PMID: 23536580
  24. Data suggest that urinary CCN3/CCN2 mRNA ratio may be a useful noninvasive biomarker for evaluating patients with nondiabetic chronic kidney disease (CKD) prior to renal biopsy. PMID: 23061738
  25. Melanocytes remaining in perilesional vitiligo skin did not express CCN3. PMID: 22507556
  26. results indicate that CCN3 enhances the migration of prostate cancer cells by increasing ICAM-1 expression through a signal transduction pathway that involves alphavbeta3 integrin, ILK, Akt and NF-kappaB PMID: 22345292
  27. Provide evidence that CCN3 enhances BMP-4 expression and bone nodule formation in osteoblasts, and that the integrin receptor, ILK, p38, JNK, and AP-1 signaling pathways may be involved. PMID: 21898398
  28. CCN3 protein regulates the decrease in Jeg3 cell numbers independent of its glycosylation status PMID: 21784733
  29. CCN3 enhances the migration of chondrosarcoma cells by increasing MMP-13 expression through the alphavbeta3/alphavbeta5 integrin receptor, FAK, PI3K, Akt, p65, and NF-kappaB signal transduction pathway. PMID: 21344378
  30. Data show reduced CCN3 levels in aRMS cells following small interfering RNA knockdown of PAX3-FKHR. PMID: 21423212
  31. CCN3 regulates the differentiation of bone resident cells to create a resorptive environment that promotes the formation of osteolytic breast cancer metastases PMID: 21514448
  32. Recombinant expression, purification, and functional characterisation of connective tissue growth factor and nephroblastoma-overexpressed protein PMID: 21209863
  33. NOV acts through alphavbeta5 integrin to activate ILK and Akt, which in turn activates c-Jun and AP-1, resulting in the activations of COX-2 and contributing the migration of human osteosarcoma cells. PMID: 21145881
  34. Only defined binding properties between Cx43 and CCN3 leading to an upregulation of CCN3 are needed for signaling. PMID: 20336664
  35. CYR61 and NOV are regulated by HIF-1alpha and TGF-beta3 in the trophoblast cell line JEG3, and their enhanced secretion could be implicated in appropriate placental invasion. PMID: 20237132
  36. CCN3 counter-regulates positive signals from TGF-beta and Wnt for fibrillin fibrillogenesis and profibrotic gene expression. PMID: 20182440
  37. These findings identify a new paracrine role of NOV in the development of cerebellar granule neurons. PMID: 19286457
  38. CCN3 suppresses neointimal thickening through the inhibition of vascular smooth cell migration and proliferation. PMID: 20139355
  39. The angiogenic gene CCN3/nov was specifically downregulated in the plexiform neurofibromas and malignant peripheral nerve sheath tumor. PMID: 20010302
  40. expression of this protein appears to be associated with a higher risk of developing metastases in Ewing's sarcoma PMID: 11891184
  41. association with Notch1 extracellular domain and inhibition of myoblast differentiation via Notch signaling pathway PMID: 12050162
  42. NOVH concentration was significantly modified in malignant but not benign adrenocortical tumors; the concentration of NOVH was significantly decreased in patients suffering from astrocytomas or multiple sclerosis PMID: 12519873
  43. in endothelial cells, CCN3 supports cell adhesion, induces directed cell migration (chemotaxis), and promotes cell survival PMID: 12695522
  44. NOVH increases cell adhesion and migration of glioblastoma cells via matrix metalloprotease 3 expression and a PDGFR-alpha dependent mechanism. PMID: 14519668
  45. evidence that adenylate cyclase as well as one or several protein kinases might be involved in the mechanoregulation of Cyr61, CTGF and Nov genes PMID: 15053922
  46. Cx43 is able to regulate cell growth via an up-regulation of NOV transcription PMID: 15181016
  47. CCN3 has a role in cutaneous wound healing in skin fibroblasts PMID: 15611078
  48. expression of CCN3 in Ewing's sarcoma primary tumors may be associated with a higher risk of developing lung and/or bone metastases PMID: 15824736
  49. Data indicates that NOV is associated with carcinogenesis and the progression of renal cell carcinoma, and the NOV expression level is different in papillary-type and clear cell-type RCC. PMID: 16145471
  50. Results suggest that NOV (nephroblastoma overexpressed) is a specific cell fate regulator in the myogenic lineage, acting negatively on key myogenic genes thus controlling the transition from progenitor cells to myoblasts. PMID: 16600215

Show More

Hide All

Subcellular Location
Secreted. Cytoplasm. Cell junction, gap junction.
Protein Families
CCN family
Tissue Specificity
Expressed in endiothelial cells (at protein level). Expressed in bone marrow, thymic cells and nephroblastoma. Increased expression in Wilms tumor of the stromal type.
Database Links

HGNC: 7885

OMIM: 164958

KEGG: hsa:4856

STRING: 9606.ENSP00000259526

UniGene: Hs.235935

CUSABIO guaranteed quality
icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2024 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1
Place an order now

I. Product details


II. Contact details


III. Ship To


IV. Bill To